Houston-based Steradian Technologies founder Asma Mirza took home third place at the annual awards. Photo by Natalie Harms/InnovationMap

A female-focused pitch competition named its top health tech startups for the fifth year running.

Ignite Healthcare Network, a Houston nonprofit founded on the mission of supporting women in health care, hosted its annual Fire Pitch Competition on November 9 at the Ion, crowning the award recipients and doling out cash prizes.

This year, Ignite accelerated 19 female health tech founders through its program that connects entrepreneurs with mentors and industry professionals. The program concludes with a select number of finalists presenting at the Fire Pitch event.

This year, eight finalists presented at the competition for judges and an audience:

  • Suchismita Acharya, CEO of Fort Worth-based AyuVis, an immunotherapy platform that's developing treatments and prevention for inflammatory and infectious diseases, specifically of the lung, kidney, skin, eye, and sepsis.
  • Piyush Modak, co-founder, vice president of research and development of New Jersey-based EndoMedix, a technology platform developing engineered biosurgery devices that address clinical needs. The first device based on this platform is PlexiClotTM Absorbable Hemostat for brain and spinal surgery.
  • Somer Baburek, co-founder and CEO of San Antonio-based HERAbiotech, which is developing a non-surgical, molecular diagnostic test for endometriosis.
  • Melissa Bowley, founder of Flourish Care, a B2B health services platform and network addressing maternal health disparities and improve outcomes. The Boston company works with health systems and insurance companies..
  • Patty Lee, co-founder and CEO of Orbit Health, a Munich-based company that uses AI and sensor technologies to develop digital health solutions for the management of Parkinson's.
  • Tawny Hammett, chief revenue officer of New York-based Paloma Health, a patient-focused technology providing holistic approach to thyroid care all from the comfort of home.
  • Meghan Doyle, CEO and co-founder of Chicago-based Partum Health, a company focused on combining specialty reproductive care, including mental health, lactation, nutrition, physical therapy, birth doula support, and more.
  • Asma Mirza, CEO and co-founder of Houston-based Steradian Technologies, creator of the RUMI, a medical device that's providing diagnostic accessibility.

Ayse McCracken, founder and board chair of Ignite, and her partners presented several prizes and awards, including naming the winners — EndoMedix won first place, Hera Biotech secured second place, and Steradian Technologies was awarded third place.

In addition to naming the three top companies, the following prizes were doled out:

  • Memorial Hermann presented AyuVis with a certificate indicating interest in a potential partnership.
  • Golden Seeds awarded a $1,000 cash prize and three hours of mentoring to Steradian Technologies.
  • Texas Children's Hospital presented Flourish Care with a certificate indicating interest in a potential partnership.
  • Southwest-Midwest National Pediatric Device Innovation Consortium awarded Hera Biotech with $20,000.
  • Houston Methodist awarded each of the three top companies with mentorship from innovation leadership.
  • JLabs presented EndoMedix with a one-year virtual residency.
  • Donna Peters, founder of The Me Suite and mentor for Ignite, presented Hera Biotech with three coaching sessions.

Last year, Joanna Nathan, CEO of Houston-based Prana Thoracic, won the top award for her company. The company went on to raise a $3 million seed round.

Earlier this year, McCracken sat down with InnovationMap to share how she's grown the program over the past five years — and why she's so passionate about what she does.

"Having an impact in the health care industry and finding solutions is important to me," McCracken says on an episode of the Houston Innovators Podcast. "The second aspect of that is there are so many women in health care, and yet you don't see them in leadership roles."

Meet the female health tech founders being accelerated by Ignite Healthcare this year. Photo courtesy of Ignite

Houston health tech accelerator names annual cohort ahead of its pitch competition

female founders

Last month, a Houston organization dedicated to supporting female founders in health care kicked off its 2023 accelerator with cohort participants from across the country.

Ignite Healthcare Network, based in Houston, is a nonprofit founded on the mission of supporting women in health care. Ignite established its 12-week accelerator program to help advance and connect female health tech founders with mentors and potential clients as their startups scale.

"We have 19 founders doing great work, and we have them matched with three to four advisors helping to mentor them," Ayse McCracken, founder and board chair of Ignite tells InnovationMap. "We also have a virtual learning program, which is new this year, and we have two sessions of those a week."

The programming is curated to tackle the health tech industry's biggest topics and provide advice for a small group of engaged startups, McCracken explains. In its fifth year now, the program has a large group of partners that are involved.

"We've had 91 companies come through our program in the last fours years," McCracken says. "They've raised over $550 million."

The cohort concludes on November 9 with the Fire Pitch Competition at the Ion, where a handful of finalists — selected by Ignite's team of mentors — will present to win the top award.

This year's cohort includes:

  • Somer Baburek, CEO and co-founder of Hera Biotech
  • Sue Carr, president and founder of CarrTech Corp
  • Suchismita Acharya, CEO, chief strategy officer, and co-founder of AyuVis
  • Asma Mirza, CEO and founder of Steradian Technologies
  • J’Vanay Santos, CEO and founder of MyLÚA Health
  • Maureen Brown, CEO and co-founder of Mosie Baby
  • Elizabeth Friedman, president and founder of Safen Medical Products
  • Meghan Doyle, CEO and co-founder of Partum Health
  • Marina Tarasova, COO and co-founder of Paloma Health
  • Melissa Bowley, CEO and founder of Flourish Care
  • Molly Hegarty, CEO and founder of Junum
  • Patty Lee, CEO and co-founder of Orbit Health
  • Piyush Modak, Vice President of R&D and co-founder of EndoMedix
  • Debbie Chen, CEO and founder of Hydrostasis
  • Rachael Grimaldi, CEO and co-founder of CardMedic
  • Rachna Dhamija, CEO of Ejenta
  • Carolyn Treviño Jenkins, CEO and co-founder of We Are Here
  • Lyn Markey, CEO and co-founder of XTremedy
  • Camille O’Malley, CTO and co-founder of XTremedy
Last year, Joanna Nathan, CEO of Houston-based Prana Thoracic, won the top award for her company.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”